Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 2/20 | 0.63 |
| ▸ | FES | P07332 | 1/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.61 |
| ▸ | TTK | P33981 | 5/20 | 0.58 |
| ▸ | ULK1 | O75385 | 1/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.51 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.51 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.50 |
| ▸ | INSR | P06213 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18018885 | 0.86 | ZAP70 (0.62) | ZAP70TTKULK1PTK2LRRK2 | |
| SCHEMBL3958582 | 0.83 | FES (0.87) | ZAP70FESFLT3TTKULK1 | |
| SCHEMBL3952918 | 0.83 | ZAP70 (0.67) | ZAP70FESFLT3TTKULK1 | |
| SCHEMBL3954360 | 0.82 | FES (0.86) | ZAP70FESFLT3TTKULK1 | |
| SCHEMBL29720306 | 0.82 | FES (0.72) | ZAP70FESFLT3TTKULK1 | |
| SCHEMBL4051190 | 0.82 | FES (0.72) | ZAP70FESFLT3TTKULK1 | |
| SCHEMBL3959984 | 0.81 | FES (0.80) | ZAP70FESFLT3TTKULK1 | |
| SCHEMBL3950201 | 0.80 | FES (0.66) | ZAP70FESFLT3TTKULK1 | |
| SCHEMBL3952863 | 0.80 | ALK (0.75) | ZAP70FESFLT3TTKULK1 | |
| SCHEMBL12781486 | 0.79 | ULK1 (0.85) | ZAP70FESFLT3ULK1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009032694-A1 | AMINO SUBSTITUTED PYRIMIDINE, PYROLLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS AND IN TREATING PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | DANA FARBER CANCER INSTITUTE (US) | 2009-03-12 | — | — | WO | claimed |
| WO-2009032703-A1 | 2- (HET) ARYLAMINO-6-AMINOPYRIDINE DERIVATIVES AND FUSED FORMS THEREOF AS ANAPLASTIC LYMPHOMA KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032703-A1 | 2- (HET) ARYLAMINO-6-AMINOPYRIDINE DERIVATIVES AND FUSED FORMS THEREOF AS ANAPLASTIC LYMPHOMA KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032694-A1 | AMINO SUBSTITUTED PYRIMIDINE, PYROLLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS AND IN TREATING PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | DANA FARBER CANCER INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032694-A1 | AMINO SUBSTITUTED PYRIMIDINE, PYROLLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS AND IN TREATING PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | DANA FARBER CANCER INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |